Maybe posted already?
link
Analysis
The launch of VascuCel will provide Admedus with another avenue to generate sales revenue.
With the recent $18.3 million capital raising complete, Admedus is in a strong financial position to drive growth and sales this financial year.
The restructure that occurred in June shows that Admedus is committed to reduce costs and focus on near-term revenue growth to create a clear path to being a sustainable, profitable, global healthcare company.
Admedus recently achieved on target sales growth, with first quarter revenue being the strongest in the history of the company.
The stock is trading at around A$0.325, which represents a large discount to its broker price targets of A$1.48, A$1.95 and A$2.00.
Ann: FDA Clearance Granted for VascuCel-AHZ.AX, page-313
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
0.240(2.04%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $11.98 | $12.00 | $11.51 | $97.20K | 8.235K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.00 | 720 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |